𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine

✍ Scribed by H Lôo; J Saiz-Ruiz; J.A Costa e Silva; M Ansseau; R Herrington; A Vaz-Serra; H Dilling; S de Risio

Book ID
114132291
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
550 KB
Volume
56
Category
Article
ISSN
0165-0327

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of tianeptine in the
Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine
✍ H. Lôo; J. Saiz-Ruiz; J. A. Costa e Silva; M. Ansseau; R. Herrington; A. Vaz-Ser 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 2 views

Depression is treated by a great variety of antidepressant treatments. SSRIs (such as fluoxetine) are well known: it is, however, sure that further progress is needed and the search for antidepressants with other mechanisms of action (such as tianeptine) or different efficacy is still of interest. A

Tianeptine versus fluoxetine in the trea
Tianeptine versus fluoxetine in the treatment of depression complicating Alzheimer's disease
✍ Tomasz M. Sobow; Marcin Maczkiewicz; Iwona Kloszewska 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 38 KB 👁 1 views

Beeching, 1991) , sometimes transferring their own disquietude at such discussions with relatives on to the reluctance of relatives to talk about DNR issues. Perhaps, in the UK, we need to learn from many of our American colleagues who see it appropriate to formulate an advance directive that comb

Controlled Comparison of Tianeptine, Alp
Controlled Comparison of Tianeptine, Alprazolam and Mianserin in the Treatment of Adjustment Disorders with Anxiety and Depression
✍ MARC ANSSEAU; MICHEL BATAILLE; GUY BRIOLE; ANDRÉ DE NAYER; PIERRE ANDRÉ FAUCHÈRE 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 439 KB 👁 2 views

A multicentre study compared tianeptine (37.5 mg/day), an original psychotropic compound characterized by both antidepressant and anxiolytic potentials, with a reference antidepressant, mianserin (60 mgkday) and a reference anxiolytic, alprazolam (1.5 mglday), in the treatment of 152 patients fulfil